The US Food and Drug Administration (FDA) has approved cosibelimab, an anti-PD-L1 antibody developed by Checkpoint Therapeutics, for the treatment of advanced skin cancer. This approval marks a significant milestone in the company’s efforts to develop innovative immunotherapies for cancer patients.
Source: https://endpts.com/checkpoint-wins-fda-approval-of-checkpoint-inhibitor-in-advanced-skin-cancer-seeks-partner-for-launch